We are excited to have Martin Mayse, our CEO and co-founder, presenting at next week's LSI USA meeting in Dana Point, CA. Don't miss his presentation on the early clinical experience and go-to-market plans with the Automatic Continuous Effusion Shunt (ACES) to treat recurrent pleural effusions. More details here: Presentation date: March 20, 2025 Time: 10:40 - 10:49 am (Track 3) #LSIUSA2025 #ImprovingOutcomes #MedTech #Innovation
Pleural Dynamics, Inc.
医疗设备制造业
Wayzata,MN 116 位关注者
Pleural Dynamics is developing best in class solutions for chronic, recurrent fluid collections within the body.
关于我们
Pleural Dynamics is a Minneapolis based medical device start-up focused on developing best in class solutions for chronic, recurrent fluid collections within the body. Our flagship product, ACES (the Automatic Continuous Effusion Shunt), is designed for the treatment of chronic recurrent pleural effusions. Chronic recurrent pleural effusions are a build-up of excess fluid between the lung and chest wall that compresses the lung and weighs on the diaphragm causing debilitating shortness of breath, irritating cough, poor quality of life, and short life expectancy. Recurrent pleural effusions affect approximately 660,000 new people in US and Europe each year and represents a $1.5B annual market opportunity for Pleural Dynamics. The current treatment options are cumbersome, costly, and based on decades old technology. ACES utilizes normal breathing motion to automatically pump pleural effusion fluid out of the chest and into the abdomen where it is quickly and safely reabsorbed by the body. This action provides continuous relief of patient symptoms while simultaneously decreasing caregiver labor, infection risk, and overall expense.
- 网站
-
https://www.pleuraldynamics.com
Pleural Dynamics, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 2-10 人
- 总部
- Wayzata,MN
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
US,MN,Wayzata,55391
Pleural Dynamics, Inc.员工
动态
-
We are pleased to share that we treated our first patient in “The ACES Study for Aseptic Pleural Effusions,” a post-market clinical study for our Novel ACES? Automatic Continuous Effusion Shunt System that is designed to automatically pump pleural effusion fluid out of the chest. Our device is the first and only fully implantable automatic effusion shunt, and plays a vital role in improving the lives of patients who suffer from intractable pleural effusion. We are excited for the future of this device and this study. https://lnkd.in/gS-cb-NF #medicaldevices #pleuraleffusion #clinicalstudy?